News · 26 weeks72+40%
2026-03-012026-08-23
Mix2890d
- Other10(36%)
- SEC Filings8(29%)
- Insider7(25%)
- Earnings2(7%)
- Offering1(4%)
Latest news
25 items- PRCerenome Highlights Presentations at the 2026 SNO/ASCO CNS Metastases Conference Demonstrating Progress in Both Therapeutics and Diagnostics Business LinesPharmacokinetic and dosimetry findings of Reyobiq from RESPECT-LM single dose study shows broad CSF compartmental distribution and on target drug activity. Update on ongoing multidose leptomeningeal metastases trial shows strong safety signal CNSide® cost-of-care analysis shows up to 47% reduction in monthly LM-related treatment costs HOUSTON, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Cerenome, Inc. (NASDAQ:CNSY) ("Cerenome" or the "Company") today highlights data from two scientific posters presented at the 2026 Society for Neuro-Oncology/American Society of Clinical Oncology (SNO/ASCO) CNS Metastases Conference, held August 13–15 in Boston. One presentation featured updated pharmacokinetic
- SECSEC Form 10-Q filed by PLUS THERAPEUTICS Inc.10-Q - CERENOME, INC. (0001095981) (Filer)
- SECPLUS THERAPEUTICS Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - CERENOME, INC. (0001095981) (Filer)
- PRCerenome Reports Second Quarter 2026 Financial Results and Business UpdateHOUSTON, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Cerenome, Inc. (NASDAQ:CNSY) ("Cerenome" or the "Company"), a CNS oncology company advancing an integrated platform that combines precision diagnostics, targeted therapeutics, and artificial intelligence, today announced financial results for the second quarter ended June 30, 2026, and provided an overview of recent and upcoming business highlights. "Our team made substantial progress this quarter in advancing our integrated CNS oncology platform including a full repositioning and rebranding of the Company," said Marc H. Hedrick, M.D., M.B.A., Cerenome President and Chief Executive Officer. "For the remainder of the year, I expect the progress to
- PRCerenome Secures In-Network Agreement with Health Care Service Corporation, Expanding CNSide® Contracted Coverage to Over 150 Million Covered LivesHOUSTON, Aug. 13, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Cerenome, Inc. (Nasdaq: CNSY) ("Cerenome" or the "Company"), announced today that it has signed an in-network provider agreement with Health Care Service Corporation ("HCSC"), effective August 1, 2026, to provide the CNSide® Cerebrospinal Fluid (CSF) Tumor Cell Enumeration (TCE) assay. HCSC represents approximately 27.3 million commercial and Medicare Advantage covered lives and operates Blue Cross and Blue Shield plans in Texas, Illinois, Montana, New Mexico, and Oklahoma and offers Medicare Advantage plans in 30 states and Washington, D.C. Combined with previously announced agreements, CNSide
- PRCerenome Selects XiFin Empower RCM for Revenue Cycle Management and Clearinghouse Services for CNSide PlatformHOUSTON, Aug. 06, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Cerenome, Inc. (NASDAQ:CNSY) ("Cerenome" or the "Company"), announced today that it has selected XiFin, Inc. ("XiFin"), a market leader in artificial intelligence (AI)-driven revenue cycle management (RCM) for diagnostic providers, to provide billing and clearinghouse services for the CNSide® Cerebrospinal Fluid (CSF) Assay Platform. The Company expects to commence billing through the XiFin platform during the third quarter of 2026, including submission of the accumulated backlog of previously performed CNSide® tests. XiFin Empower RCM provides end-to-end revenue cycle infrastructure purpose-b
- SECPLUS THERAPEUTICS Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits8-K - CERENOME, INC. (0001095981) (Filer)
- PRCerenome Launches as an Integrated CNS Oncology CompanyHOUSTON, July 31, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ:PSTV) (the "Company"), today announces that its corporate rebrand to Cerenome will be completed as scheduled. Effective August 3, 2026, the Company’s name will become Cerenome, Inc. The Company's common stock will begin trading on the Nasdaq Capital Market under the new ticker symbol "CNSY," effective market open on the same day. The new name reflects the Company's de facto evolution from a therapeutics-focused organization into an integrated CNS oncology company. The Company has expanded beyond targeted radiotherapeutics because effective solutions for CNS cancer will require a multimodal approach. Cerenome will i
- PRPlus Therapeutics Announces Scientific Presentations and Sponsored Symposium at 2026 SNO/ASCO CNS Metastases ConferenceHOUSTON, July 28, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ:PSTV) (the "Company"), a healthcare company developing and commercializing targeted therapeutics and diagnostics for central nervous system ("CNS") cancers, today announced two posters highlighting its ReSPECT-LM clinical development program and CNSide® cerebrospinal fluid ("CSF") diagnostic platform will be presented at the 2026 Society for Neuro-Oncology/American Society of Clinical Oncology ("SNO/ASCO") CNS Metastases Conference, being held August 13–15, 2026, in Boston, Massachusetts. The Company and its wholly owned subsidiary, CNSide Diagnostics, LLC, will also host a sponsored symposium titled "Redefining th
- PRPlus Therapeutics Secures Regional Coverage Agreement with Medical Mutual for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS CancerHOUSTON, July 21, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV) ("Plus" or the "Company"), announced today that it has signed a regional agreement with Medical Mutual effective July 1, 2026, covering approximately 1.2 million people throughout Ohio and Kentucky, to provide the CNSide® Cerebrospinal Fluid (CSF) Tumor Cell Enumeration (TCE) assay. This brings CNSide CSF TCE assay total contracted coverage to approximately 127 million people. The CNSide® CSF Assay Platform supports rapid diagnoses, treatment monitoring, and treatment guidance for patients with leptomeningeal metastases. The superior clinical utility of C
- PRPlus Therapeutics and Genomic Testing Cooperative Partner to Integrate Next-Generation Sequencing Into the CNSide® CSF Assay PlatformHOUSTON and LAKE FOREST, Calif., July 16, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ:PSTV) ("Plus" or the "Company") and Genomic Testing Cooperative, LCA ("GTC") today announced a collaboration to integrate GTC’s next-generation sequencing (NGS) technology into the CNSide® cerebrospinal fluid (CSF) assay platform. The collaboration is expected to enable comprehensive DNA and RNA profiling across hundreds of clinically relevant biomarkers from a single CSF specimen, extending CNSide from guideline-recognized CTC enumeration into the guideline-recognized DNA and tumor-derived DNA analytic layer within one integrated platform. The collaboration advances Plus’ three-pillar CNS on
- PRPlus Therapeutics Highlights NCCN CNS Cancers Guidelines Update and Reinforces Clinical Role of CNSide® in Leptomeningeal Metastases MonitoringHOUSTON, July 14, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ:PSTV) ("Plus" or the "Company"), today highlighted the recent update to the National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for Central Nervous System Cancers, including guidance relevant to leptomeningeal metastases (LM), a serious and often underdiagnosed complication of advanced cancer. The updated NCCN CNS Cancers Guidelines reinforce that cerebrospinal fluid (CSF) analysis remains a standard component of LM diagnosis and disease assessment and that, in patients receiving intrathecal therapy, CSF cytology is typically re-evaluated every four to eight weeks alongside MRI a
- INSIDERDirector Andrews Ronald Asbury converted options into 922 shares (SEC Form 4)4 - PLUS THERAPEUTICS, INC. (0001095981) (Issuer)
- INSIDERChief Financial Officer Sims Andrew John Hugh Macintyre converted options into 2,985 shares, increasing direct ownership by 43% to 9,941 units (SEC Form 4)4 - PLUS THERAPEUTICS, INC. (0001095981) (Issuer)
- INSIDERDirector Hawkins Richard J converted options into 922 shares, increasing direct ownership by 152% to 1,529 units (SEC Form 4)4 - PLUS THERAPEUTICS, INC. (0001095981) (Issuer)
- INSIDERDirector Van Es-Johansson An converted options into 922 shares (SEC Form 4)4 - PLUS THERAPEUTICS, INC. (0001095981) (Issuer)
- INSIDERDirector Clowes Howard converted options into 922 shares, increasing direct ownership by 87% to 1,981 units (SEC Form 4)4 - PLUS THERAPEUTICS, INC. (0001095981) (Issuer)
- INSIDERChief Executive Officer Hedrick Marc H converted options into 16,439 shares, increasing direct ownership by 59% to 44,483 units (SEC Form 4)4 - PLUS THERAPEUTICS, INC. (0001095981) (Issuer)
- INSIDERDirector Guse Kyle converted options into 922 shares (SEC Form 4)4 - PLUS THERAPEUTICS, INC. (0001095981) (Issuer)
- PRPlus Therapeutics Provides Mid-Year Business Update Including Corporate RebrandingPlus Therapeutics to become Cerenome, to trade under new Nasdaq ticker CNSY on August 3, 2026 Affirms 2026 guidance on key milestones Reports positive CNSide® commercial progress HOUSTON, June 30, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ:PSTV) ("Plus" or the "Company"), a healthcare company focused on central nervous system ("CNS") cancers, today provides a comprehensive business update. Notably, the Company announces it is changing its company name from Plus Therapeutics to Cerenome and Nasdaq ticker to CNSY, effective August 3, 2026. Furthermore, the Company affirmed its anticipated 2026 milestones guidance, including commercial guidance around its CNSide Diagnostics
- PRPlus Therapeutics Secures National Coverage Agreement with Elevance Health for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS CancerHOUSTON, June 25, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV) ("Plus" or the "Company"), announced today that it has signed a national agreement with Elevance Health, Inc. (NYSE: ELV), effective May 1, 2026, covering approximately 45.4 million people throughout the United States, to provide the CNSide® Cerebrospinal Fluid (CSF) Tumor Cell Enumeration (TCE) assay. This brings CNSide CSF TCE assay total contracted coverage to 126 million people. The CNSide® CSF Assay Platform supports rapid diagnoses, treatment monitoring, and treatment guidance for patients with leptomeningeal metastases. The superior clinical utilit
- PRPlus Therapeutics to Provide Business Update Call on June 30, 2026HOUSTON, June 23, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ:PSTV) ("Plus" or the "Company"), a healthcare company focused on central nervous system ("CNS") cancers, today announced that management will host a business update conference call and webcast on Tuesday, June 30, 2026, at 8:30 a.m. Eastern Time. During the call, management will focus on the Company’s CNSide® diagnostic launch and its integrated development plan for lead drug Reyobiq. Furthermore, management will provide further detail on its CNS oncology strategy and native artificial intelligence development plans. "Our team is making substantial progress in all 3 areas of the company, specifically diagnostics,
- SECSEC Form S-8 filed by PLUS THERAPEUTICS Inc.S-8 - PLUS THERAPEUTICS, INC. (0001095981) (Filer)
- SECSEC Form EFFECT filed by PLUS THERAPEUTICS Inc.EFFECT - PLUS THERAPEUTICS, INC. (0001095981) (Filer)
- SECPLUS THERAPEUTICS Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits8-K - PLUS THERAPEUTICS, INC. (0001095981) (Filer)
PSTV FAQ
6 questionsWhat does PLUS THERAPEUTICS Inc. do?
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium NanoLiposomes, a patented radiotherapy for patients with recurrent glioblastoma, which is in the Phase 1 dose-finding clinical trial. The company is also developing DocePLUS, a patented chemotherapy for patients with solid tumors that is in Phase 1 clinical trial; and DoxoPLUS, a generic chemotherapy for patients with ovarian cancer. It has a license agreement with NanoTx...Where does PSTV stock trade?
PLUS THERAPEUTICS Inc. (PSTV) is listed on NASDAQ.What sector and industry is PSTV in?
PLUS THERAPEUTICS Inc. operates in the Health Care sector, Medical/Dental Instruments industry.What are analysts saying about PSTV?
PLUS THERAPEUTICS Inc. has had 3 recent analyst actions on file. The most recent action was from Lake Street: Buy with a $200.00 price target on 2026-02-03. Recent price targets range from $200.00 to $900.00.What companies are similar to PSTV?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), BDX (Becton Dickinson and Company), MDLN (Medline Inc.). Compare PSTV side-by-side with any of them on Quantisnow.How can I track PSTV on Quantisnow?
Quantisnow aggregates PLUS THERAPEUTICS Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow PSTV to receive live email and push alerts on every new disclosure.